<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The majority of patients with systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> with associated clonal, hematological non-mast cell lineage disease (<z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e>) have a myeloid stem cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> including <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), myelodysplastic/<z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), or <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>The clinicopathologic features of <z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e> have not been fully characterized </plain></SENT>
<SENT sid="2" pm="."><plain>We describe seven cases of this entity: 3 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 3 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 1 with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In the majority of cases, SM was diagnosed concurrently with the <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> and aberrant mast cell <z:mp ids='MP_0000002'>morphology</z:mp> was observed </plain></SENT>
<SENT sid="4" pm="."><plain>The commonly described c-kit enzymatic site mutation Asp816Val was detected only in 2 cases, while 3 patients carried the Asp816His mutation </plain></SENT>
<SENT sid="5" pm="."><plain>Among the 3 cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 2 patients carried the translocation t(8;21) </plain></SENT>
<SENT sid="6" pm="."><plain>On the basis of our results and other reported cases, there appears to be a specific association between SM and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with t(8;21) </plain></SENT>
<SENT sid="7" pm="."><plain>Concurrent occurrence of SM may define a subset of patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and other <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> who have an adverse prognosis </plain></SENT>
<SENT sid="8" pm="."><plain>As clinically effective <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> that inhibit enzymatic-type c-kit mutations are being developed, detection of mast cell proliferation associated with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> may have important therapeutic implications </plain></SENT>
</text></document>